Advance in Precision Prevention and Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
PENG Lan, XIA Tianliang, CHEN Mingyuan*
NPC (nasopharyngeal carcinoma) is the head and neck malignant tumour with the highest invasivenessand metastasis rate, and recurrence/metastasis is the main reason for its treatment failure. Follow-up is significantfor early detection of recurrent/metastatic lesions in NPC, and the continuous improvement in the follow-up strategy can help to achieve early diagnosis and treatment of RM-NPC (recurrent/metastatic nasopharyngeal carcinoma). This review details the different diagnostic tools for each of locoregional recurrence and distant metastasis of NPC. In terms of drug therapy, the development of immunotherapy, targeted therapy and the continuous optimisation of combination therapy have led to breakthroughs in the treatment of RM-NPC, which is not suitable for local treatment. This review summarises current advances at the forefront of drug therapy in terms of first-, secondand third-line systemic therapy, respectively. As for local therapy, radiotherapy includes radiotherapy for recurrent NPC and metastatic NPC, and surgery includes recurrent surgery of the nasopharynx and neck and recurrent surgery of the retropharynx. Advances in local therapy techniques and combination with drug therapy have made their application in RM-NPC more widespread and effective.
CN
EN